Certified by Founder Lodge
Forbion
Netherlands - Naarden
INVESTOR
1 Disclosed Funding Rounds $12,500,000
19 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Forbion was born out of ABN AMRO Capital Life Sciences, the latter being co-founded by Sander Slootweg, Martien van Osch and Bart Bergstein in 2000. Six years later, we transitioned to Forbio
| Company | Date | Round | Raised |
|---|---|---|---|
 SynOx Therapeutics |
April, 23 ,2024 | Series B | $75,000,000 |
 Seamless Therapeutics |
March, 17 ,2023 | Series A | $12,500,000 |
 Pheon Therapeutics |
May, 21 ,2024 | Series B | $120,000,000 |
 Complement Therapeutics |
April, 18 ,2023 | Series A | $78,929,000 |
 Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
 AAVantgarde Bio |
June, 07 ,2023 | Series A | $65,333,745 |
 Beacon Therapeutics |
July, 10 ,2024 | Series B | $170,000,000 |
 Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
 F2G |
September, 13 ,2024 | Unknown | $100,000,000 |
 Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
 Aiolos Bio |
October, 26 ,2023 | Series A | $245,000,000 |
 Engrail Therapeutics |
March, 20 ,2024 | Series B | $157,000,000 |
 Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| SynOx Therapeutics |
April, 23 ,2024 | Series B | $75,000,000 |
| Pheon Therapeutics |
May, 21 ,2024 | Series B | $120,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Beacon Therapeutics |
July, 10 ,2024 | Series B | $170,000,000 |
| F2G |
September, 13 ,2024 | Unknown | $100,000,000 |
 LoQus23 Therapeutics Ltd |
October, 02 ,2024 | Series A | $46,550,175 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Alvara Protocol | $10,000,000 | (Oct 22, 2024)
Rollstack | $11,000,000 | (Oct 22, 2024)
Biological Lattice Industries | $1,800,000 | (Oct 22, 2024)
SchooLinks | $80,000,000 | (Oct 22, 2024)
MyFO | $3,500,000 | (Oct 22, 2024)
